Protocol Ledger

NCT03849118 · Phase III · COMPLETED

89Zr-TLX250 for PET/CT Imaging of ccRCC- ZIRCON Study

Interventional Phase III clinical trial protocol NCT03849118 sponsored by Telix Pharmaceuticals (Innovations) Pty Limited in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-08-15 Enrollment: 300 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03849118
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)300 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03849118
Protocol FieldVerified Registry Value
NCT IdentifierNCT03849118
Consolidated Lead SponsorTelix Pharmaceuticals (Innovations) Pty Limited
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment300 participants (ACTUAL)
Registered Start Date2019-08-15
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI